Get the Stockscreener App
18.63
2.15%
-0.41
After Hours:
18.88
0.25
+1.34%
Castle Biosciences Inc stock is traded at $18.63, with a volume of 552.39K.
It is down -2.15% in the last 24 hours and down -19.46% over the past month.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
See More
Previous Close:
$19.04
Open:
$18.95
24h Volume:
552.39K
Relative Volume:
1.43
Market Cap:
$565.05M
Revenue:
$344.23M
Net Income/Loss:
$-24.16M
P/E Ratio:
-21.99
EPS:
-0.8471
Net Cash Flow:
$28.33M
1W Performance:
-24.27%
1M Performance:
-19.46%
6M Performance:
-46.50%
1Y Performance:
+9.33%
1-Day Range:
$18.35
$19.23
1-Week Range:
$18.31
$25.23
52-Week Range:
$14.59
$44.28
Castle Biosciences Inc Stock (CSTL) Company Profile
Name
Castle Biosciences Inc
Sector
Industry
Phone
866-788-9007
Address
1500 W. PARKWOOD AVE., FRIENDSWOOD, TX
Compare CSTL vs TMO, DHR, IDXX, WAT, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
18.63 | 577.48M | 344.23M | -24.16M | 28.33M | -0.8471 |
TMO
Thermo Fisher Scientific Inc
|
459.30 | 168.20B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
166.26 | 117.86B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
533.92 | 41.97B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
352.21 | 34.17B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
112.90 | 31.50B | 7.07B | 1.29B | 993.00M | 4.5355 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Apr-30-21 | Initiated | Lake Street | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Dec-27-19 | Reiterated | Canaccord Genuity | Buy |
| Aug-19-19 | Initiated | BTIG Research | Buy |
| Aug-19-19 | Initiated | Canaccord Genuity | Buy |
| Aug-19-19 | Initiated | Robert W. Baird | Outperform |
| Aug-19-19 | Initiated | SVB Leerink | Outperform |
View All
Castle Biosciences Inc Stock (CSTL) Latest News
Castle Biosciences recognized for driving progress in global healthcare with AdvanceAD-Tx accolade - Traders Union
Castle Biosciences, Inc. (CSTL) Latest Stock News & Headlines - Yahoo Finance
Castle Biosciences' AdvanceAD-Tx™ Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation - PR Newswire
Price-Driven Insight from (CSTL) for Rule-Based Strategy - Stock Traders Daily
TradingKey - TradingKey
Derek Maetzold, Castle Biosciences CEO, sells $217,904 in shares By Investing.com - Investing.com Australia
Derek Maetzold, Castle Biosciences CEO, sells $217,904 in shares - Investing.com
Castle Biosciences (CSTL) CEO sells shares and exercises stock options in pre-planned trades - Stock Titan
Castle Biosciences (NASDAQ:CSTL) Cut to "Sell" at Wall Street Zen - MarketBeat
Castle Biosciences, Inc. (CSTL) Stock Analysis: A Promising 145.58% Upside Potential - DirectorsTalk Interviews
CSTL Achieves Strong Q1 Revenue, Raises 2026 Guidance - GuruFocus
CSTL Maintained by Baird -- Price Target Lowered to $43 - GuruFocus
Wall Street analysts predict an 85.15% upside in Castle Biosciences (CSTL): Here's what you should know - MSN
Derek Maetzold files Form 144 to sell CSTL (NASDAQ: CSTL) shares - Stock Titan
Castle Biosciences Down Over 15%, on Pace for Largest Percent Decrease Since July 2024 -- Data Talk - Moomoo
Castle Biosciences (NASDAQ:CSTL) Shares Gap Down Following Analyst Downgrade - MarketBeat
CCORF Maintains Castle Biosciences(CSTL.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Castle Biosciences Q1 2026 slides: revenue beats, guidance raised By Investing.com - Investing.com Australia
Castle Biosciences (NASDAQ:CSTL) Price Target Lowered to $43.00 at Robert W. Baird - MarketBeat
Castle Biosciences targets $345M-$355M 2026 revenue as TissueCypher volumes grow 58% and AdvanceAD-Tx reaches ~650 orders - MSN
Castle Biosciences, Inc. (NASDAQ:CSTL) Q1 2026 Earnings Call Transcript - Insider Monkey
Castle Biosciences (NASDAQ:CSTL) Releases Earnings Results, Hits Expectations - MarketBeat
Castle Biosciences, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Castle Biosciences Q1 Earnings Call Highlights - MarketBeat
CSTL: Strong Q1 2026 results with raised guidance, record test volumes, and improved financials - TradingView
Castle (CSTL) Q1 2026 Earnings Transcript - AOL.com
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Castle Biosciences Q1 2026 slides: revenue beats, guidance raised - Investing.com
Earnings call transcript: Castle Biosciences Q1 2026 sees revenue growth - Investing.com
Earnings call transcript: Castle Biosciences Q1 2026 sees revenue growth By Investing.com - Investing.com South Africa
Castle Biosciences Posts Strong Q1 Results, Raises 2026 Guidance - TipRanks
Earnings Flash (CSTL) Castle Biosciences, Inc. Posts Q1 Adjusted Loss $0.49 per Share, vs. FactSet Est of $-0.49 - marketscreener.com
Earnings Flash (CSTL) Castle Biosciences, Inc. Reports Q1 Revenue $83.7M, vs. FactSet Est of $79.2M - marketscreener.com
Castle Biosciences (NASDAQ: CSTL) Q1 2026 revenue, loss and test growth - Stock Titan
Castle Biosciences (NASDAQ: CSTL) lifts 2026 outlook after Q1 core test growth - Stock Titan
Castle Biosciences Reports First Quarter 2026 Results – Company Announcement - Financial Times
EDIT's Q1 Loss Narrower Than Expected, Pipeline in Focus - The Globe and Mail
Castle Biosciences Q1 2026 Earnings Call Transcript - MarketBeat
Wall Street Analysts Predict an 85.15% Upside in Castle Biosciences (CSTL): Here's What You Should Know - Yahoo Finance
Free skin cancer screenings roll out nationwide with Castle support - Stock Titan
Castle Biosciences Supports Nationwide Patient Advocacy and Screening Initiatives to Celebrate Skin Cancer Awareness Month - Barchart.com
CSTL Stock Price, Quote & Chart | CASTLE BIOSCIENCES INC (NASDAQ:CSTL) - ChartMill
Castle Biosciences to present new Mayo Clinic research on TissueCypher test at Digestive Disease Week - Traders Union
Mayo Clinic data: Barrett's test changed surveillance in 55% - Stock Titan
New Data at DDW 2026 Show TissueCypher® Testing Improves Risk Stratification and Drives Risk-Aligned Management in Barrett's Esophagus - Sahm
Castle Biosciences, Inc. $CSTL Shares Sold by AIGH Capital Management LLC - MarketBeat
(CSTL) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Earnings Preview: CSTL to Report Financial Results Post-market on May 06 - Moomoo
Castle Biosciences (NASDAQ:CSTL) Upgraded to Strong-Buy at Zacks Research - MarketBeat
Castle Biosciences (CSTL) to Release Earnings on Wednesday - MarketBeat
What makes Castle Biosciences (CSTL) a good fit for 'trend investing' - MSN
Castle Biosciences Inc Stock (CSTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.89%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):